1. Home
  2. BODI vs ACET Comparison

BODI vs ACET Comparison

Compare BODI & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Beachbody Company Inc.

BODI

The Beachbody Company Inc.

HOLD

Current Price

$10.37

Market Cap

71.2M

Sector

Industrials

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$8.09

Market Cap

71.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BODI
ACET
Founded
1998
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
71.2M
71.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BODI
ACET
Price
$10.37
$8.09
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$8.00
$96.67
AVG Volume (30 Days)
63.4K
232.6K
Earning Date
11-10-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$282,565,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.38
$7.15
52 Week High
$12.33
$17.44

Technical Indicators

Market Signals
Indicator
BODI
ACET
Relative Strength Index (RSI) 50.47 87.36
Support Level $9.44 $7.94
Resistance Level $10.76 $8.55
Average True Range (ATR) 0.90 0.33
MACD -0.22 0.73
Stochastic Oscillator 32.24 89.64

Price Performance

Historical Comparison
BODI
ACET

About BODI The Beachbody Company Inc.

The Beachbody Co Inc is a health and wellness platform providing fitness, nutrition and stress-reducing programs to its customers. The product offerings of the company include Digital Subscriptions, Nutritional Products, and Connected Fitness Products. It earns the majority of its revenue from the United States. The company operates and manages its business in one operating segment. Majority of revenue is through Digital.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: